Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Menn, Petra ^a   Weber, Norbert ^b   Holle, Rolf ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Asklepios Clinic München   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EUROQOL 5 DIMENSION; FEMALE; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SHORT FORM 12; ST GEORGE RESPIRATORY QUESTIONNAIRE; COMPARATIVE STUDY; GERMANY; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PSYCHOMETRY; QUESTIONNAIRE;

AGED; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 77950847059     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-39     Document Type: Article

References (24)

1. Geldmacher H, Biller H, Herbst A, Urbanski K, Allison M, Buist AS, Hohlfeld JM, Welte T. [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr 2008, 133:2609-2614. 10.1055/s-0028-1105858, 19052996.
2. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796. 10.1016/S0140-6736(07)61382-8, 17765528.
3. Nowak D, Dietrich ES, Oberender P, Uberla K, Reitberger U, Schlegel C, Albers F, Ruckdaschel S, Welsch R. [Cost-of-illness Study for the Treatment of COPD in Germany]. Pneumologie 2004, 58:837-844. 10.1055/s-2004-830143, 15597250.
4. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?. Chest 2006, 130:1117-1128. 10.1378/chest.130.4.1117, 17035446.
5. Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F, Lofdahl CG, Lundback B. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005, 3:56. 10.1186/1477-7525-3-56, 1215504, 16153294.
6. Garrido P, Diez J, Gutierrez J, Centeno A, Vazquez E, de Miguel A, Carballo M, Garcia R. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006, 4:31. 10.1186/1477-7525-4-31, 1488827, 16719899.
7. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
8. Szende A, Leidy N, Stahl E, Svensson K. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009, 18:267-272. 10.1007/s11136-008-9429-z, 19105049.
9. Doll H, Miravitlles M. Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005, 23:345-363. 10.2165/00019053-200523040-00005, 15853435.
10. Nishimura K, Sato S, Tsukino M, Hajiro T, Ikeda A, Koyama H, Oga T. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2009, 7:69. 10.1186/1477-7525-7-69, 2723082, 19624834.
11. Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hébert PC. Measurement of Short-term Changes in Dyspnea and Disease-Specific Quality of Life Following an Acute COPD Exacerbation. Chest 2002, 121:688-696. 10.1378/chest.121.3.688, 11888946.
12. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J of Clin Pract 2007, 61:1112-1120.
13. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2008). , http://www.goldcopd.org
14. The EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. 10.1016/0168-8510(90)90421-9, 10109801, The EuroQol Group.
15. Greiner W, Claes C, Busschbach JJV, Graf von der Schulenburg JM. Validating the EQ-5D with Time Trade Off for the German Population. Eur J Health Econ 2005, 6:124-130. 10.1007/s10198-004-0264-z, 19787848.
16. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
17. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42:851-859. 10.1097/01.mlr.0000135827.18610.0d, 15319610.
18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
19. Tritchler D. Interpreting the standardized difference. Biometrics 1995, 51:351-353. 10.2307/2533342, 7766789.
20. Rosner B, Glynn RJ, Lee ML. The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics 2006, 62:185-192. 10.1111/j.1541-0420.2005.00389.x, 16542245.
21. Rosner B, Glynn RJ, Lee ML. Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics 2003, 59:1089-1098. 10.1111/j.0006-341X.2003.00125.x, 14969489.
22. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12:1061-1067. 10.1002/hec.787, 14673814.
23. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13:873-884. 10.1002/hec.866, 15362179.
24. Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009, 10:15-23. 10.1007/s10198-008-0097-2, 18327677.